mProX™ Human NTRK1 Stable Cell Line

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;PANC-1;MDA-MB-231

Target Classification

Kinase Cell Lines

Target Research Area

CNS Research

Related Diseases

Insensitivity To Pain, Congenital, With Anhidrosis; Thyroid Carcinoma, Familial Medullary

Gene ID

Human:4914

UniProt ID

Human:P04629

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

NTRK1 is a gene that has been found to be involved in various types of tumors. In recent studies, NTRK1 fusions have been identified in soft tissue tumors, including sarcomas, and have shown good clinical response to targeted therapies such as larotrectinib. NTRK2, another gene in the NTRK family, has also been found to be involved in tumorigenesis, particularly in adult soft tissue tumors. The highly selective Trk tyrosine kinase inhibitors, including larotrectinib, have shown significant efficacy in treating tumors with NTRK fusions. NTRK2 fusions are less common compared to NTRK1 and NTRK3 fusions, but they have been identified in sarcomas with features reminiscent of solitary fibrous tumors, and patients have responded well to larotrectinib therapy. The identification of NTRK2 fusions in soft tissue tumors could significantly improve clinical outcomes through selective NTRK inhibitor therapy, especially in the first-line setting. Prompt RNA-based next-generation sequencing testing at initial diagnosis may benefit these patients. Additionally, NTRK fusions have been found in pediatric spindle cell tumors, where they have diagnostic relevance and can be targeted for therapy. Overall, the detection of NTRK1/2/3 gene fusions in tumor samples can be achieved through cost-efficient methods, providing an alternative to conventional analysis techniques.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human NTRK1 Stable Cell Line (S01YF-1023-PY117). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Skyler Miller (Verified Customer)

How does NTRK1 fusion affect ovarian cancer? Jan 26 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

NTRK1 gene fusion, such as TPM3-NTRK1, can occur in ovarian cancer, and its presence may influence the effectiveness of certain therapies like entrectinib. Jan 26 2021

chat Casey Garcia (Verified Customer)

What is the role of NTRK1 in prostate cancer prognosis? Dec 19 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

Downregulation of NTRK1 in prostate cancer is associated with poor prognosis and lower levels of tumor-infiltrating immune cells. Dec 19 2020

Published Data

Fig.1 Cell proliferation inhibition is achieved through the knockdown of NTRK1.

In the upper panel, immunoblot analyses were conducted using antibodies against NTRK1, pLATS1 (S909), LATS1, pYAP (S127), YAP, MST1 (Thr183), or MST1, along with GAPDH antibodies as a loading control, on lysates derived from PANC1 or MDA-MB231 cells transfected with siCon or siNTRK1. In the lower panel, cell numbers were assessed at 24-hour intervals over a 72-hour period in siCon or siNTRK1-transfected PANC-1 or MDA-MB-231 cells, with three independent experiments conducted. Error bars denote standard deviation, and statistical significance (*P < 0.05) was determined by a two-tailed Student's t-test.

Ref: Yang, Xinyuan, et al. "NTRK1 is a positive regulator of YAP oncogenic function." Oncogene 38.15 (2019): 2778-2787.

Pubmed: 30542115

DOI: 10.1038/s41388-018-0609-1

Research Highlights

Lin, Ruihe. et al. "Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy." Diagnostic pathology, 2023.
The three NTRK genes have been extensively studied, among which NTRK2 stands out for its intricate structural features and role in tumorigenesis of various types of tumors. Currently, only two genes, STRN and RBPMS, have been identified in fusion with NTRK2 in adult soft tissue tumors. Most recently, highly selective Trk tyrosine kinase inhibitors, such as larotrectinib and entrectinib, have exhibited remarkable success in treating tumors with NTRK fusions and have received FDA approval.
Lin, Ruihe. et al. "Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy." Diagnostic pathology, 2023.
Pubmed: 37865792 DOI: 10.1186/s13000-023-01400-1

Donati, Michele. et al. "Spitz tumor with RAF1 fusion: A report of 3 cases." Annals of diagnostic pathology, 2023.
The study discusses Spitz tumors, a type of melanocytic neoplasms that have unique characteristics such as spindled and/or epithelioid cells and specific changes in the stromal and epidermal components. These tumors are associated with fusion kinases involving certain genes, including ALK, ROS1, NTRK1, NTRK2, NTRK3, MET and RET, BRAF, and MAP3K8, as well as HRAS mutations. Recently, RAF1 fusions have also been discovered in cutaneous melanocytic neoplasms, including conventional melanoma, congenital nevus, and BAP-1 inactivated tumors. The current study presents three cases of Spitz neoplasms with RAF1 fusions, including a previously reported CTDSPL::RAF1 fusion and two new PPAP2B::RAF1 and ATP2B4::RAF1 fusions. Two cases were classified as Spitz nevus, while the third was categorized as Spitz melanoma due to additional features, such as 9p21 homozygous deletion and positive sentinel lymph node biopsy. These findings suggest that RAF1 fused melanocytic neoplasms may be a unique subgroup of Spitz tumors, with RAF1 fusion acting as an oncogenic driver.
Donati, Michele. et al. "Spitz tumor with RAF1 fusion: A report of 3 cases." Annals of diagnostic pathology, 2023.
Pubmed: 37856952 DOI: 10.1016/j.anndiagpath.2023.152215